Cargando…

Burden of illness of Pompe disease in patients only receiving supportive care

BACKGROUND: Pompe disease is an orphan disease for which enzyme replacement therapy (ERT) recently became available. This study aims to estimate all relevant aspects of burden of illness—societal costs, use of home care and informal care, productivity losses, and losses in health-related quality of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanters, Tim A., Hagemans, Marloes L. C., van der Beek, Nadine A. M. E., Rutten, Frans F. H., van der Ploeg, Ans T., Hakkaart, Leona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173621/ https://www.ncbi.nlm.nih.gov/pubmed/21499718 http://dx.doi.org/10.1007/s10545-011-9320-x

Ejemplares similares

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
por: Kanters, Tim A, et al.
Publicado: (2014)

A conceptual disease model for adult Pompe disease
por: Kanters, Tim A., et al.
Publicado: (2015)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
por: Kanters, Tim A., et al.
Publicado: (2017)

Impact of enzyme replacement therapy on survival in adults with Pompe disease
por: Güngör, Deniz, et al.
Publicado: (2013)

The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients
por: van Capelle, Carine I., et al.
Publicado: (2011)

PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe disease
por: Hagemans, Marloes L. C., et al.
Publicado: (2010)

Hearing in adults with Pompe disease
por: van der Beek, Nadine A. M. E., et al.
Publicado: (2011)

Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy
por: Güngör, Deniz, et al.
Publicado: (2011)

Enzyme replacement therapy and fatigue in adults with Pompe disease
por: Güngör, Deniz, et al.
Publicado: (2013)

Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study
por: Güngör, Deniz, et al.
Publicado: (2013)

Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients
por: van der Meijden, Jan C., et al.
Publicado: (2018)

Public support for neonatal screening for Pompe disease, a broad-phenotype condition
por: Weinreich, Stephanie Shifra, et al.
Publicado: (2012)

Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up
por: Güngör, Deniz, et al.
Publicado: (2015)

Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy
por: van der Meijden, Jan C., et al.
Publicado: (2018)

Diffusion tensor imaging of the brain in Pompe disease
por: van den Dorpel, Jan J. A., et al.
Publicado: (2022)

Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study
por: Ditters, Imke A. M., et al.
Publicado: (2023)

Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study
por: van der Beek, Nadine AME, et al.
Publicado: (2012)

Phenotypical variation within 22 families with Pompe disease
por: Wens, Stephan C A, et al.
Publicado: (2013)

MRI changes in diaphragmatic motion and curvature in Pompe disease over time
por: Harlaar, Laurike, et al.
Publicado: (2022)

Fatigue in neuromuscular disorders: focus on Guillain–Barré syndrome and Pompe disease
por: de Vries, J. M., et al.
Publicado: (2009)

Fatigue: an important feature of late-onset Pompe disease
por: Hagemans, M. L. C., et al.
Publicado: (2007)

Chest MRI to diagnose early diaphragmatic weakness in Pompe disease
por: Harlaar, Laurike, et al.
Publicado: (2021)

Extension of the Pompe mutation database by linking disease‐associated variants to clinical severity
por: Niño, Monica Y., et al.
Publicado: (2019)

Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience
por: Niño, Monica Y., et al.
Publicado: (2020)

Positive association between physical outcomes and patient-reported outcomes in late-onset Pompe disease: a cross sectional study
por: Yuan, Meng, et al.
Publicado: (2020)

Are Anti-rhGAA Antibodies a Determinant of Treatment Outcome in Adults with Late-Onset Pompe Disease? A Systematic Review
por: Ditters, Imke A. M., et al.
Publicado: (2023)

Effects of exercise training in 23 adults with Pompe disease receiving enzyme therapy
por: van den Berg, Linda, et al.
Publicado: (2013)

Is the brain involved in patients with late‐onset Pompe disease?
por: van den Dorpel, Jan J. A., et al.
Publicado: (2022)

Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease
por: Harlaar, Laurike, et al.
Publicado: (2019)

Neurofilament Light and Its Association With CNS Involvement in Patients With Classic Infantile Pompe Disease
por: Mackenbach, Maarten J., et al.
Publicado: (2023)

Long-term benefits of physical activity in adult patients with late onset Pompe disease: a retrospective cohort study with 10 years of follow-up
por: Ismailova, Gamida, et al.
Publicado: (2023)

From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: a Pipeline for the Development of Antisense Oligonucleotides
por: Bergsma, Atze J, et al.
Publicado: (2016)

Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolism
por: Canibano‐Fraile, Rodrigo, et al.
Publicado: (2022)

A genetic modifier of symptom onset in Pompe disease
por: Bergsma, Atze J., et al.
Publicado: (2019)

Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long‐term clinical outcome of classic infantile Pompe patients
por: Poelman, Esther, et al.
Publicado: (2020)

Association of Muscle Strength and Walking Performance in Adult Patients With Pompe Disease
por: Favejee, Marein M, et al.
Publicado: (2018)

Cognitive outcome of classic infantile Pompe patients receiving enzyme therapy
por: Ebbink, BJ, et al.
Publicado: (2013)

Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease
por: van Kooten, Harmke A., et al.
Publicado: (2022)

Minutes of the European POmpe Consortium (EPOC) Meeting March 27 to 28, 2015, Munich, Germany
por: Schoser, Benedikt, et al.
Publicado: (2015)

Burden of illness of hip fractures in elderly Dutch patients
por: Kanters, T. A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nf9obbth6r6k0b7gv99h1v1nf0